Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dyskalemia in Hypertensive Patients Initiating Telmisartan/Amlodipine FDC
NCT05155436Phase 4Completed
- Sponsor
- National Heart Foundation of Bangladesh
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telmisartan and amlodipine in hypertension (HTN), sponsored by National Heart Foundation of Bangladesh. Primary endpoints: Prevalent dyskalemia at baseline and Incident dyskalemia after 2 months of therapy. Started Jan 2022; status: completed.
02
Drugs
telmisartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05155436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155436.